加载中
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
收盘时
US$2.17
−US$0.08 · -3.56%
盘后
US$2.1536
−US$0.0164 · -0.76%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
日内区间
当前US$2.17
52周区间
当前US$2.17
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
36
偏贵
情绪
49
多空交织
风险
53
风险偏高
动量
79
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
日内区间
当前US$2.17
52周区间
当前US$2.17
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 919.3万 USD | — | 586.9万 USD | — | — |
| 毛利 | −919.3万 USD | — | −586.9万 USD | — | — |
| 研究与开发 | 9042.9万 USD | 9674.4万 USD | 9090.4万 USD | 9089.7万 USD | 6341.2万 USD |
| 销售、一般及管理费用 | 3156.8万 USD | 3145万 USD | 3487.7万 USD | 2805.8万 USD | 2301.7万 USD |
| 营业费用 | 1.12亿 USD | 1.28亿 USD | 1.26亿 USD | 1.19亿 USD | 8642.9万 USD |
| 利息收入 | 1549.4万 USD | 1931.7万 USD | 1410.7万 USD | 558.8万 USD | 37万 USD |
| 利息支出 | — | — | — | 558.8万 USD | — |
| 折旧和摊销 | 919.3万 USD | 915.2万 USD | 586.9万 USD | 263.7万 USD | 175.6万 USD |
| 营业利润 | −1.21亿 USD | −1.28亿 USD | −1.32亿 USD | −1.19亿 USD | −8642.9万 USD |
| 净利润 | −1.04亿 USD | −1.09亿 USD | −1.18亿 USD | −1.14亿 USD | −8607.5万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI424.66万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM260.91万0.00%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF162.47万0.00%954亿 USD0.05%US$233.52-0.63%
Vanguard Russell 2000 ETFVTWO69.42万0.00%180亿 USD0.06%US$112.27-0.35%
Dimensional - US Small Cap ETFDFAS46.61万0.00%338.69亿 USD0.31%US$78.17-0.23%
iShares Micro-Cap ETFIWC32.04万0.02%13.17亿 USD0.60%US$181.66-0.73%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM24万0.21%1.17亿 USD0.73%US$15.8484-0.58%
Invesco RAFI US 1500 Small-Mid ETFPRFZ22.66万0.01%26.7亿 USD0.36%US$52.92-0.45%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMInvesco RAFI US 1500 Small-Mid ETFPRFZAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
